{"preliminary_commentary":{"by_channel":{"youtube":1,"podcast":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["amivantamab","capmatinib"]],"indication":"unresectable metastatic non-small cell lung cancer","name":"METalmark","nct_id":"NCT05488314","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=metalmark-nct05488314. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"METalmark","arms":[{"description":"Participants will receive capmatinib 400 milligrams (mg) orally twice daily from Cycle 1 Day 1, in combination with amivantamab 700 mg intravenous (IV) infusion (for body weight less than 80 kilograms \\[kg\\]) or 1050 mg IV infusion (for body weight greater than or equal to 80 kg) once weekly from Cycle 1 Day 1 for 4 weeks and then every 2 weeks from Week 5 (Cycle 2; each cycle of 28 days). Doses will be escalated or de-escalated based on the dose limiting toxicities (DLTs) and the recommended Phase 2 combination dose (RP2CD) will be determined by the study evaluation team (SET).","label":"Phase 1 (Combination Dose Selection)","type":"EXPERIMENTAL"},{"description":"Participants with mesenchymal-epithelial transition (MET) exon 14 skipping mutation who are treatment naïve (Cohort 1A), who have received prior therapy (Cohort 1B), or participants with MET amplification who have received prior therapy (Cohort 1C) will receive capmatinib in combination with amivantamab at the RP2CD determined by the SET in Phase 1.","label":"Phase 2 (Dose Expansion)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":57,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Capmatinib","otherNames":[],"type":"DRUG"},{"name":"Amivantamab","otherNames":["JNJ-61186372"],"type":"DRUG"}],"last_update":"2026-11-03","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2027-04-28","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase 1: Number of Participants with Adverse events (AEs) by Severity","timeFrame":"Up to 2 years 1 month"},{"measure":"Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs)","timeFrame":"Cycle 1 (Day 1 through Day 28)"},{"measure":"Phase 2: Objective Response Rate","timeFrame":"Up to 2 years 1 month"}],"references":[],"start_date":{"date":"2022-12-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT05488314"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/metalmark-nct05488314"}